US nod for Dabur's Pfizer's Camptosar marketing

Chennai, Oct 30 (UNI) Dabur Pharma Limited, a leading oncology player, today announced that the US Food Drug Administration has granted tentative approval to company's Abbreviated New Drug Applications (ANDA) to market its generic version of Pfizer's Camptosar injection.

In a release here, the company said it would begin marketing the drug in the US upon expiry of the patent in February 2008.

Irinotecan, which had sales of over USD 500 million in the US was indicated as a component of first line therapy in combination with five fluorouracil and leucovorin for the patients with metastatic carcinoma of the colon or rectum, the release added.

UNI